Literature DB >> 11921283

Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: relationship to clinicopathological parameters.

Keiichi Kondo1, Masahiro Yao, Minoru Yoshida, Takeshi Kishida, Taro Shuin, Takeshi Miura, Masatoshi Moriyama, Kazuki Kobayashi, Naoki Sakai, Shigeki Kaneko, Satoshi Kawakami, Masaya Baba, Noboru Nakaigawa, Yoji Nagashima, Yukio Nakatani, Masahiko Hosaka.   

Abstract

To delineate more precisely the somatic von Hippel-Lindau disease (VHL) gene alteration as well as to elucidate its etiologic role in renal tumorigenesis, we examined a total of 240 sporadic renal cell carcinomas (RCCs) for somatic VHL gene alterations by DNA-SSCP followed by sequencing, methylation-specific PCR assay, microsatellite LOH study, and Southern blot analysis. Intragenic mutation of the VHL gene was found exclusively in clear-cell or variant-type RCCs at a frequency of 51% (104/202). Hypermethylation of the VHL promoter region was detected in an additional 11 clear-cell RCCs. Microsatellite analysis demonstrated that LOH of the VHL locus was found in 140/155 (90%) informative clear-cell RCCs. The VHL gene therefore seems to be inactivated in a two-hit manner by intragenic mutation or hypermethylation plus allelic loss in clear-cell RCC. Genomic rearrangement of the VHL gene detected by Southern analysis was not found (0/216 cases); this is in contrast to germ lines in which Southern aberrations consisted of 7-19% of the mutations. Clinicopathologic data demonstrated that VHL mutation/LOH did not vary according to tumor progression in clear-cell RCC, including tumor diameter, stage, grading, distant metastasis, and lymph node metastasis. Interestingly, VHL mutation was significantly less frequent in RCCs occurring in younger (< or = 55 years) than that in older (> or = 56 years) patients. These data suggested that the inactivation of the VHL tumor-suppressor gene is a specific genetic change in clear-cell RCC, and that it may occur at an early or first step in the clear-cell tumorigenic pathway rather than as a late event. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11921283     DOI: 10.1002/gcc.10054

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  58 in total

1.  Using Molecular Biology to Develop Drugs for Renal Cell Carcinoma.

Authors:  C Lance Cowey; W Kimryn Rathmell
Journal:  Expert Opin Drug Discov       Date:  2008-03       Impact factor: 6.098

2.  Epidermal growth factor receptor expression in renal cell carcinoma: rationale for therapy with sidling blockade.

Authors:  Ronald M Bukowski
Journal:  Curr Oncol Rep       Date:  2005-03       Impact factor: 5.075

Review 3.  Systemic therapies for metastatic renal cell carcinoma in older adults.

Authors:  Sumanta K Pal; Ari Vanderwalde; Arti Hurria; Robert A Figlin
Journal:  Drugs Aging       Date:  2011-08-01       Impact factor: 3.923

4.  Mutational status of VHL gene and its clinical importance in renal clear cell carcinoma.

Authors:  Mariana Rezende Alves; Felipe Cavalcanti Carneiro; André Mourão Lavorato-Rocha; Walter Henriques da Costa; Isabela Werneck da Cunha; Stênio de Cássio Zequi; Gustavo Cardoso Guimaraes; Fernando Augusto Soares; Dirce Maria Carraro; Rafael Malagoli Rocha
Journal:  Virchows Arch       Date:  2014-07-16       Impact factor: 4.064

Review 5.  Hypoxia, Hypoxia-inducible Transcription Factors, and Renal Cancer.

Authors:  Johannes Schödel; Steffen Grampp; Eamonn R Maher; Holger Moch; Peter J Ratcliffe; Paul Russo; David R Mole
Journal:  Eur Urol       Date:  2015-08-19       Impact factor: 20.096

Review 6.  Alterations in VHL as potential biomarkers in renal-cell carcinoma.

Authors:  Lucy Gossage; Tim Eisen
Journal:  Nat Rev Clin Oncol       Date:  2010-04-06       Impact factor: 66.675

7.  Efficacy of targeted therapy for metastatic renal cell carcinoma in the elderly patient population.

Authors:  Husain K Khambati; Toni K Choueiri; Christian K Kollmannsberger; Scott North; George A Bjarnason; Ulka N Vaishampayan; Lori Wood; Jennifer J Knox; Min-Han Tan; Mary J MacKenzie; Frede Donskov; Brian I Rini; Daniel Y C Heng
Journal:  Clin Genitourin Cancer       Date:  2014-03-05       Impact factor: 2.872

8.  Hypoxia-inducible factor-dependent degeneration, failure, and malignant transformation of the heart in the absence of the von Hippel-Lindau protein.

Authors:  Li Lei; Steve Mason; Dinggang Liu; Yan Huang; Carolyn Marks; Reed Hickey; Ion S Jovin; Marc Pypaert; Randall S Johnson; Frank J Giordano
Journal:  Mol Cell Biol       Date:  2008-02-19       Impact factor: 4.272

9.  VHL Type 2B gene mutation moderates HIF dosage in vitro and in vivo.

Authors:  C M Lee; M M Hickey; C A Sanford; C G McGuire; C L Cowey; M C Simon; W K Rathmell
Journal:  Oncogene       Date:  2009-03-02       Impact factor: 9.867

10.  Absence of VHL gene alteration and high VEGF expression are associated with tumour aggressiveness and poor survival of renal-cell carcinoma.

Authors:  J-J Patard; N Rioux-Leclercq; D Masson; S Zerrouki; F Jouan; N Collet; C Dubourg; B Lobel; M Denis; P Fergelot
Journal:  Br J Cancer       Date:  2009-09-15       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.